Pulmatrix, Inc. (PULM)

Market Cap	5.26M -70.6%
Revenue (ttm)	n/a
Net Income	-4.03M
EPS	-1.10
Shares Out	3.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,196
Open	1.400
Previous Close	1.433
Day's Range	1.380 - 1.460
52-Week Range	1.160 - 5.498
Beta	1.90
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 15, 2026

About PULM

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: PULM
• Website: https://www.pulmatrix.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 19, 2026

Data Sources Report a data error